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Abstract
Diabetes mellitus is a common disease in dogs and cats. The most common form of
diabetes in dogs resembles type 1 diabetes in humans. Studies suggest that genetics, an
immune-mediated component, and environmental factors are involved in the development
of diabetes in dogs. A variant of gestational diabetes also occurs in dogs. The most common
form of diabetes in cats resembles type 2 diabetes in humans. A major risk factor in cats is
obesity. Obese cats have altered expression of several insulin signaling genes and glucose
transporters and are leptin resistant. Cats also form amyloid deposits within the islets
of the pancreas and develop glucotoxicity when exposed to prolonged hyperglycemia.
This review will briefly summarize our current knowledge about the etiology of diabetes
in dogs and cats and illustrate the similarities among dogs, cats, and humans.
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Introduction
Diabetes mellitus is a common disorder in dogs and cats,
with a reported hospital prevalence rate of w0.4–1.2%.
Classic clinical signs of diabetes include polyuria, poly-
dipsia, polyphagia, and weight loss. Clinical signs do not
develop until hyperglycemia reaches a concentration that
results in glycosuria, typically at blood glucose concen-
trations of 180–220 mg/dl in dogs and 220–270 mg/dl in
cats. A subclinical or prediabetic state as occurs in humans
is uncommonly recognized in dogs and cats. The diagnosis
of diabetes is based on the presence of appropriate clinical
signs and persistent hyperglycemia and glycosuria.
Hypercholesterolemia and hypertriglyceridemia are com-
mon and ketonuria and ketoacidosis may develop if the
owner fails to recognize early signs or is lax in seeking
veterinary care. Treatment options are similar to those for
human diabetics and include insulin injections (usually
administered twice a day at 12 h intervals), dietary
modifications, correction of obesity, exercise in dogs, and
oral hypoglycemic medications in cats. The treatment
approach differs between dogs and cats, in part, because the
underlying etiology differs. Traditionally, the classification
of diabetes mellitus in dogs and cats has more or less
followed the scheme used in human medicine (American
Diabetes Association (ADA) 2013). Although the etiopatho-
genic mechanisms may not be completely identical, the
‘human model’ provides a guide for identification and
differentiation of the various forms of the disease in dogs
and cats. Diabetes in dogs resembles type 1 diabetes in
humans while diabetes in most cats resembles type 2
diabetes. This article focuses on our current understanding
of the etiology of diabetes in dogs vs cats and illustrates the
similarities among dogs, cats, and humans.
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This paper forms part of a thematic review series on Animal Models of Disease. The
Guest Editor for this section was Alan Conley, University of California at Davis, Davis,
CA, USA.
Type 1 diabetes mellitus: dogs
The most common clinically recognized form of diabetes
mellitus in the dog resembles type 1 diabetes mellitus in
humans and is characterized by permanent hypoinsuline-
mia, essentially no increase in endogenous serum insulin
or C-peptide concentrations following administration of
an insulin secretagogue (e.g., glucose, glucagon, and
amino acids), and an absolute necessity for exogenous
insulin to maintain control of glycemia, avoid ketoaci-
dosis, and survive (Montgomery et al. 1996). Virtually all
dogs are insulin dependent at the time when diabetes
mellitus is diagnosed. Common histological abnormalities
in dogs include a reduction in the number and size of
pancreatic islets, a decrease in the number of b-cells within
islets, and b-cell vacuolation and degeneration. An
extreme form of the disease may occur in juvenile dogs,
represented by an absolute deficiency of b-cells and
pancreatic islet hypoplasia or aplasia. Less severe changes
involving the pancreatic islets and b-cells may predispose
the adult dog to diabetes mellitus after the dog has been
exposed to environmental factors, such as insulin-
antagonistic diseases and drugs, and pancreatitis.
The etiology of type 1 diabetes in dogs is undoubtedly
multifactorial (Table 1). Genetic predispositions have been
suggested by familial associations, pedigree analysis of
Keeshonds, and genomic studies aimed at identification of
susceptibility and protective major histocompatibility
complex haplotypes (Table 2; Guptill et al. 2003, Kennedy
et al. 2006, Fall et al. 2007). A number of genes linked with
susceptibility to diabetes in humans are associated with an
increased risk of diabetes in dogs (Catchpole et al. 2013).
Diabetes in dogs has been associated with major histo-
compatibility complex class II genes (dog leukocyte
antigen (DLA)), with similar haplotypes and genotypes
being identified in the most susceptible breeds. A region
containing a variable number of tandem repeats and
several polymorphisms has been identified in the canine
insulin gene, with some alleles associated with suscep-
tibility or resistance to diabetes in a breed-specific manner
(Catchpole et al. 2013).
Studies suggest an immune-mediated component
in the development of diabetes in some dogs. Immune-
mediated insulitis characterized by infiltration of
Table 1 Potential factors involved in the etiopathogenesis of
diabetes mellitus in dogs and cats
Dog Cat
Genetics Islet amyloidosis
Immune-mediated insulitis Obesity
Pancreatitis Pancreatitis
Obesity Concurrent hormonal disease
Concurrent hormonal disease Hyperadrenocorticism
Hyperadrenocorticism Acromegaly
Diestrus-induced excess
growth hormone
Hyperthyroidism
Hyperthyroidism
Drugs
Drugs
Progestogens
Glucocorticoids
Glucocorticoids
Progestogens
Infection
Infection
Concurrent illness
Concurrent illness
Kidney disease
Kidney disease
Cardiac disease
Cardiac disease
Hyperlipidemia (?)
Hyperlipidemia
Genetics (Burmese cat)
Immune-mediated insulitis (?)
Table 2 Breeds with a significantly (P!0.05) decreased or
increased risk of diabetes mellitus (VeterinaryMedical Data Base,
1970–1999)a
Breed Cases Control Odds ratio
Australian terrier 37 1 32.10
Standard schnauzer 105 19 4.78
Samoyed 175 45 3.36
Miniature schnauzer 624 172 3.13
Fox terrier 91 26 3.02
Keeshond 57 20 2.45
Bichon frise 50 18 2.40
Finnish spitz 35 13 2.32
Cairn terrier 67 28 2.07
Miniature poodle 737 356 1.79
Siberian husky 80 45 1.53
Toy poodle 208 139 1.29
Mixed breed 1860 1609 1.00
(Reference)
Beagle 73 94 0.67
English setter 30 42 0.61
Labrador retriever 246 364 0.58
Basset hound 33 50 0.57
Dalmatian 28 45 0.53
Doberman pinscher 109 182 0.51
Irish setter 68 121 0.48
Boston terrier 31 68 0.39
Shih tzu 31 69 0.38
Brittany 28 64 0.37
Old english sheepdog 14 35 0.35
Norwegian elkhound 10 26 0.33
Golden retriever 108 294 0.31
English pointer 11 36 0.26
Cocker spaniel 90 307 0.25
Great dane 15 54 0.24
Bulldog 7 26 0.23
Shetland sheepdog 29 107 0.23
Collie 25 109 0.19
Pekingese 14 66 0.18
German shepherd 70 365 0.16
Airedale terrier 8 45 0.15
German shorthaired
pointer
6 37 0.14
Boxer 7 82 0.07
aData from Guptill et al. (2003).
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lymphocytes into the islets has been described and
antibodies directed against islet cells, insulin, proinsulin,
intracellular glutamic acid decarboxylase 65 (GAD65), and
insulinoma antigen 2 (IA2) have been identified in
diabetic dogs (Hoenig & Dawe 1992, Davison et al. 2003,
2008, 2011). The presence of circulating autoantibodies
against insulin, proinsulin, GAD65, and IA2 usually
precedes the development of hyperglycemia or clinical
signs in humans with type 1 diabetes. A similar sequence
of events may also occur in dogs although the onset of
type 1 diabetes typically occurs in dogs that are at 8 years
of age or older. Canine diabetes appears to more closely
resemble latent autoimmune diabetes of adult humans
(Andersen et al. 2010). Seemingly, autoimmune
mechanisms, in conjunction with genetic and environ-
mental factors, insulin-antagonistic diseases and drugs,
and pancreatitis all play a potential role in the initiation
and progression of diabetes in dogs. The end result is a loss
of b-cell function, hypoinsulinemia, impaired transport of
circulating glucose into most cells, accelerated hepatic
gluconeogenesis and glycogenolysis, and the subsequent
development of hyperglycemia and glycosuria. Loss of
b-cell function is irreversible in dogs with type 1 diabetes
and lifelong insulin therapy is mandatory to maintain
glycemic control of the diabetic state.
Type 1 diabetes mellitus: cats
In contrast to the dog, type 1 diabetes is considered rare
in cats. Lymphocytic infiltration into the islets (insulitis)
as a marker of immune-mediated disease has only been
described in a few cats (Minkus et al. 1991, Hall et al. 1997).
In a recent study examining islet lesions in a larger group
of diabetic cats against a control population (matched in
age, sex, and body weight), a tendency of lymphocytes to
be more frequent in diabetic cats was found (20% of
diabetic cats vs 5% of control cats), but the infiltration was
usually mild and may reflect an inflammatory situation
also known to be present in type 2 diabetes (Zini et al.
2012). Only one of the 27 diabetic cats had severe
lymphocytic infiltration, which was similar in severity to
those described in the two studies mentioned above
(Fig. 1). b cell and insulin antibodies have so far not
been demonstrated in newly diagnosed diabetic cats
(Hoenig et al. 2000).
Type 2 diabetes mellitus: cats
Approximately 80% of diabetic cats suffer from a type 2-
like diabetes mellitus that is a heterogeneous disease
attributable to a combination of impaired insulin action in
liver, muscle, and adipose tissue (insulin resistance), and
Figure 1
Pancreatic histology. Severe infiltrations with T lymphocytes within
a pancreatic islet in an 18-year-old DSH cat with diabetes mellitus.
This is a rare finding, usually only few or no lymphocytes are
found in islets of diabetic cats. Immunohistochemistry for CD3,
HE counterstain (!40).
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b-cell failure. Environmental as well as genetic factors are
thought to play a role in the development of both defects.
Genetic factors have just started to be investigated in the
cat (Forcada et al. 2014). It is likely that diabetes in the
cat is a polygenic disease and that many genes will be
associated with an increased risk for the disease. The most
convincing evidence of a genetic basis comes from
studies in the Burmese cat. In breeding lines from
Australia, New Zealand, and the United Kingdom, the
frequency of diabetes was shown to be approximately four
times higher in Burmese cats than in domestic cats and in
some families of Burmese cats more than 10% of the
offspring were affected by diabetes (McCann et al. 2007,
Lederer et al. 2009).
One of the major risk factors for the development of
diabetes in cats is obesity. Others include sex (males higher
risk than females), physical inactivity and indoor confine-
ment, increasing age, and the administration of gluco-
corticoids and progestins (Panciera et al. 1990, McCann
et al. 2007, Prahl et al. 2007, Slingerland et al. 2009). It has
been shown that obese cats are 3.9 times more likely to
develop diabetes mellitus compared with cats with an
optimal body weight (Scarlett & Donoghue 1998).
Experimental studies in healthy cats showed that an
average weight gain of 1.9 kg during a feeding trial was
associated with a decrease in insulin sensitivity of more
than 50% (Appleton et al. 2001). Similar results were
reported in another trial in which each kilogram increase
in weight led to w30% loss in insulin sensitivity (Hoenig
et al. 2007). Insulin sensitivity differs considerably
between individuals and it has been suggested that cats
with intrinsically low insulin sensitivity are at an increased
risk of developing glucose intolerance with weight gain.
Male cats tended to have lower insulin sensitivity before
the feeding trial and gained more weight than female cats,
which might explain in part why male cats are at an
increased risk of developing diabetes mellitus (Appleton
et al. 2001). The effect of sex steroids on differences in
insulin sensitivity and weight gain in male vs female cats
has not been reported.
The mechanisms of insulin resistance on a cellular level
and the interrelations of the different findings are not yet
understood in cats. Most of the research to date has focused
on glucose transporters, insulin signaling genes in insulin-
sensitive tissues, and secretion of adipocytokines from
adipose tissue. In cats that became obese, the expression of
the insulin-sensitive glucose transporter GLUT4 (SLC2A4)
in muscle and fat was significantly lower than that in lean
cats, whereas the expression of GLUT1 (SLC2A1), which is
not insulin sensitive, remained unchanged (Brennan et al.
2004). Expression of several insulin signaling genes in liver
and skeletal muscles was significantly lower in obese cats
than in lean cats, which is similar in humans with insulin
resistance (Mori et al. 2009). Also similar to humans, it is
now recognized in cats that adipose tissue is an active and
complex endocrine organ. Adiponectin, which is almost
exclusively produced in adipose tissue, decreases with
obesity and diabetes mellitus in cats (Hoenig et al. 2007).
Adiponectin enhances insulin sensitivity and has anti-
inflammatory properties; a decrease, therefore, contributes
to insulin resistance and inflammation. Leptin, the
‘prototypic’ adipokine, is involved in appetite suppression
and energy expenditure and plays a role in modulation of
insulin sensitivity (Radin et al. 2009). Obese cats have been
found to be leptin resistant, i.e., they have much higher
leptin concentrations than lean cats without causing an
appropriate physiological response (Hoenig 2012). Adipose
tissue secretes a number of proinflammatory cytokines and
obesity is now considered a state of low-grade chronic
inflammation. TNFa was the first adipose-derived factor
suggested to represent a link between obesity and the
insulin resistance observed in human type 2 diabetes; this
cytokine exerts a strong negative influence on insulin
signaling. Today, various additional cytokines and chemo-
kines (e.g., IL6 and MCP1) are also known to be involved in
the inflammatory process in humans. Adipose tissue in cats
may behave in a similar manner, as the level of TNFa (in fat)
was significantly higher in obese cats than in lean cats
(Hoenig et al. 2006).
Insulin resistance evolving during weight gain is
reversible after weight loss. When healthy cats were fed
ad libitum, weight gain was associated with a significant
increase in glucose and insulin concentrations during an
intravenous glucose tolerance test (IVGTT) compared with
baseline and the total amount of insulin secretion was
significantly higher. Several weeks after achieving weight
loss by intake of low-calorie diets, the results of the
IVGTT were similar to those at baseline (Biourge et al.
1997, Fig. 2).
Although obesity induces insulin resistance, not all
obese cats develop diabetes mellitus. Presumably for
diabetes to develop, there must be b-cell dysfunction
leading to impaired glucose tolerance and eventually
type 2 diabetes. Unfortunately, there is minimal infor-
mation on b-cell function and insulin secretion in cats
during the natural development of diabetes. Most studies
have been conducted on healthy cats in which obesity was
induced within a short period of time by feeding ad libitum.
One hypothesis to explain the loss of b-cell function in
type 2 diabetes involves b-cell destruction by amyloid
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deposition. Islet amyloid is derived from a hormone
named islet amyloid polypeptide (IAPP) also known as
amylin. IAPP is a normal product of the b-cells, is stored
with insulin in secretory vesicles, and is co-secreted with
insulin into the circulation. IAPP levels are elevated in
conditions associated with insulin resistance, e.g., in
cats with obesity (Henson et al. 2011). Cats, humans,
and nonhuman primates have an amyloidogenic
amino acid structure of IAPP with the potential to form
amyloid depositions within the islets of the pancreas
(O’Brien 2002, Hull et al. 2004). Islet amyloid deposits
have not been identified in hamsters, rats, mice, or dogs
while IAPP and amyloid deposits have been identified in
canine endocrine tumors (Jordan et al. 1990, O’Brien et al.
1990). Amyloid depositions have been found in many cats
with diabetes but are also a frequent finding in non-
diabetic cats. In a recent study, 56% of diabetic cats and
42% of control cats matched for age, sex, and body weight
had amyloid depositions, the amount of which was also
comparable (Zini et al. 2012; Fig. 3). It is not known as to
why some but not all diabetic cats develop amyloid
deposits and whether amyloid is a cause or consequence
of the disease. Disturbed protein folding and/or trafficking
of amylin within the b-cell lead to the formation of toxic
oligomers. These intracellular molecules induce cyto-
toxicity and may lead to a decline in b-cell function and
to b-cell apoptosis. The extracellular amyloid deposits
seem to be less toxic and represent the end point of
misfolding (Costes et al. 2013). Loss of b-cell function may
be present before amyloid depositions are visible.
Misfolding may be a reflection of another defect within
the b-cell and not the primary cause of b-cell dysfunction.
When present, however, these abnormalities may
accelerate further damage.
Hyperglycemia is an additional factor, which has a
negative impact on b-cell function and survival in cats, a
phenomenon known as glucotoxicity (Link et al. 2013).
There is little doubt whether glucotoxicity is a secondary
event, as hyperglycemia becomes apparent only after
b-cells start to fail. However, improving glycemic control
by insulin therapy will reverse some of the negative effects
of glucotoxicity and reversal of glucotoxicity is an
important mechanism to explain diabetic remission in
cats (Nelson et al. 1999). The cellular mechanisms through
which chronic hyperglycemia affects insulin secretion and
insulin sensitivity are poorly understood. In humans, it
has been proposed that oxidative stress and inflammatory
cytokines play an important role (Robertson 2009, Donath
& Shoelson 2011). In a recent study, glucose-induced
lesions in b-cells were investigated in cats (Zini et al. 2009).
After 10 days of i.v. glucose infusion, healthy cats had 50%
fewer b-cells per islet area than healthy control cats that
were not infused. Islet cells showed apoptotic features and
were caspase 3 (a marker for apoptosis) positive (Fig. 4).
Interestingly, hyperglycemia induced a systemic inflam-
matory response, characterized by an increased plasma
concentration of a1-acid glycoprotein. Systemic inflam-
mation has also been described in human type 2 diabetes.
Lipotoxicity is the term used for the deleterious
effect of high circulating concentrations of free fatty
acids on b-cell function. Lipotoxicity may not be as
important as glucotoxicity in cats (Zini et al. 2009). In
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Figure 2
Mean serum glucose (A) and insulin (B) concentrations (GS.E.M.) in 12 cats
after i.v. administration of 0.5 g glucose/kg of body weight at entry into the
study (baseline), after 9G2 months of weight gain, after a voluntary fast of
5–6 weeks (weight loss), and 5 weeks after the end of fasting (recovery).
a–c: points with a different letter are significantly different (P!0.05)
among periods. Note the development of impaired glucose tolerance
despite increased insulin secretion with weight gain and improvement in
glucose tolerance and the exaggerated insulin secretory response with
weight loss. Reproduced, with permission, from Biourge et al. (1997).
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contrast to the deleterious impact of a 10-day glucose
infusion on b-cells, lipid infusion over the same time
period did not affect plasma insulin or glucose concen-
trations or results in b-cell apoptosis. In human medicine,
it has been proposed that glucotoxicity occurs indepen-
dent of lipotoxicity, whereas lipotoxicity requires
increased blood glucose levels to fully manifest. This
may also apply to cats.
Type 2 diabetes mellitus: dogs
Obesity-induced insulin resistance has been documented
in dogs but progression to type 2 diabetes does not occur
(Verkest et al. 2012). Studies suggest that at least some
of the etiopathogenic mechanisms responsible for the
development of obesity-associated type 2 diabetes in
humans and cats do not occur in dogs. For example,
b-cell sensitivity to changes in glucose and the first phase
of the insulin secretory response by the b-cell are lost in
humans and cats but not in dogs despite years of obesity-
induced insulin resistance and compensatory hyper-
insulinemia (Verkest et al. 2011a). In humans, loss of the
first phase of insulin secretion is an important early
marker of b-cell failure (Gerich 2002).
IAPP forms toxic intracellular oligomers in b-cells in
humans and cats but not in dogs and amylin does not
aggregate extracellularly as histologically visible amyloid
in the pancreatic islets in dogs (Haataja et al. 2008,
Scheuner & Kaufman 2008). Circulating concentrations
of the adipocyte-secreted hormone adiponectin are
Figure 3
Pancreatic histology. Islet amyloidosis in a 16-year-old female spayed DSH cat with diabetes mellitus (H & E,!40).
Figure 4
Pancreatic isletsofhealthycatsafter receiving0.9%NaCl, i.v. glucose infusion,
and intravenous lipids for 10days. No lesionswere observed in the control cat
and in the cat that received lipids. In the glucose-infused cat, a large area of
the islet appeared devoid of nuclei and included several vacuoles, suggesting
hydropic degeneration. Hydropic degeneration of islet cells indicates the
accumulation of glycogen. The remaining islet nuclei appear larger than
that in the control cat. (H & E,!40). Reproduced from Zini et al. (2009),
with kind permission from Springer Science and Business Media.
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decreased in obese humans and low adiponectin concen-
trations predict progression to type 2 diabetes in humans
(Li et al. 2009). By contrast, circulating adiponectin
concentrations were not lower in chronically obese dogs,
compared with lean dogs, and adiponectin was not
associated with insulin sensitivity in obese dogs (Verkest
et al. 2011b). Although adiponectin does not appear to
play a role in the development of canine obesity-
associated insulin resistance, adiponectin receptors are
present on pancreatic b-cells and adiponectin has been
shown to protect b-cells against fatty acid-induced
apoptosis (Kharroubi et al. 2003, Rakatzi et al. 2004).
Other specific types of diabetes: dogs and cats
The category ‘other specific types’ refers to diabetes that
develops in association with diseases or factors other than
those described under type 1 or type 2 diabetes mellitus.
A large number of genetic syndromes are listed in this
category for humans but similar syndromes have not been
described in dogs or cats. Diabetes may occur secondary to
disorders of the exocrine pancreas and any process that
diffusely injures the pancreas can cause diabetes, most
notably pancreatitis. The incidence of histologically identi-
fiable often severe pancreatitis in diabetic dogs is 30–40%
and is believed to be a contributing factor in the
development of diabetes and diabetic ketoacidosis in
affected dogs (Watson et al. 2010, Bostrom et al. 2013). The
cause and effect relationship of pancreatitis and diabetes in
cats is difficult to define. Histological abnormalities consist-
ent with pancreatitis were found in 22–57% of diabetic cats
and in 60 and 67% of nondiabetic cats (Kraus et al. 1997,
Goossens et al. 1998, De Cook et al. 2007, Zini et al. 2012).
According to the currently available data and the impression
of the authors,pancreatitis isnot a frequent causeofdiabetes
mellitus in cats. Although in principle, severe pancreatitis
with extensive tissue destruction may result in damage of
the pancreatic islets and b-cell loss, but unlike dogs this
seems to be a rare event in cats. Pancreatitis, however, seems
to be a frequent co-morbidity in diabetic cats.
Several endocrinopathies, most notably hypercortiso-
lism (hyperadrenocorticism) in the dog and hypersomato-
tropism (acromegaly) in the cat cause severe insulin
resistance and are frequently diagnosed at the time of or
within weeks of establishing the diagnosis of diabetes
(Table 1). Similarly, the administration of diabetogenic
drugs, most notably glucocorticoids and progestins, may
cause glucose intolerance and overt diabetes in dogs and
cats that presumably have pre-existing b-cell defect, islet
pathology, or both. Dogs and cats that become euglycemic
after correcting for insulin resistance are considered
subclinical diabetics.
Gestational diabetes: dogs
A fourth category in the human classification model is
gestational diabetes, which is defined as carbohydrate
intolerance with onset or first recognition during preg-
nancy (ADA 2013). A syndrome resembling gestational
diabetes in humans occurs in older female dogs but not in
cats. Female dogs ovulate at w7-month intervals and
serum progesterone concentration is increased for
2 months after ovulation and formation of corpora lutea.
Progesterone stimulates growth hormone secretion from
the canine mammary gland and both hormones cause
insulin resistance and carbohydrate intolerance in the dog
(Selman et al. 1992). Older female dogs are frequently
diagnosed with diabetes during diestrus or pregnancy
when serum progesterone and growth hormone concen-
trations are increased (Fall et al. 2008a, 2010, Mared et al.
2012). Documenting increased baseline serum insulin
concentration supports the presence of functional
b-cells. These dogs presumably have an adequate mass of
functional b-cells to maintain carbohydrate tolerance
when insulin resistance is not present (e.g., during periods
of ovarian inactivity when progesterone concentrations
remain low (!0.5 ng/ml)), but they are unable to secrete
an adequate amount of insulin to maintain euglycemia in
the presence of insulin resistance (Fall et al. 2008b). Early
recognition and improvement in insulin resistance after
ovariectomy, while some b-cell functions are still present,
may reestablish euglycemia without the long-term need
for insulin therapy. Failure to quickly correct insulin
resistance often results in progressive loss of b-cells and a
greater likelihood for permanent insulin dependency to
control hyperglycemia (Fall et al. 2010).
In summary, our current knowledge suggests that the
etiological factors involved in the development of diabetes
mellitus are similar in dogs, cats, and humans. However,
the predominant type of diabetes managed by veterinar-
ians differs between the dog and cat. Immune-mediated
diseases are very common in dogs, hence it is not
surprising that type 1 diabetes predominates. By contrast,
immune-mediated disease is very uncommon in cats and
type 1 diabetes is not recognized in this species. Cats have
an amyloidogenic amino acid structure of IAPP with the
potential to form amyloid depositions within the islets
of the pancreas during periods of sustained insulin
resistance, as occurs with obesity. Obese cats also develop
other derangements that promote the development of
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diabetes; hence type 2 diabetes is predominant in this
species. Dogs do not have an amyloidogenic amino acid
structure of IAPP and do not develop islet amyloidosis
during periods of sustained insulin resistance. This may
explain, in part, why type 2 diabetes is not recognized in
dogs, even when they are morbidly obese.
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